1. Overview
FLi1 (Friend leukemia integration 1) is a transcription factor encoded by the FLi1 gene and functions as a proto-oncogene. It is also known as transcription factor ERGB and belongs to the ETS (E-26 transformation-specific) family of transcription factors. Members of this family are involved in key developmental processes, including vasculogenesis, angiogenesis, hematopoiesis, and bone development.
FLi1 plays a significant role in regulating gene expression during blood cell development and vascular formation. Abnormal expression or mutation of the FLi1 gene has been implicated in various malignancies, particularly those of hematologic and vascular origin.
2. Symptoms
FLi1 alterations do not directly produce symptoms; instead, clinical manifestations arise from the diseases in which FLi1 is involved. In hematologic malignancies, patients may present with symptoms related to bone marrow dysfunction, such as anemia, thrombocytopenia, or leukemic manifestations.
In solid tumors and vascular neoplasms, symptoms depend on tumor location and extent. In Ewing sarcoma and endothelial tumors, clinical features are associated with tumor growth, local invasion, and systemic effects of malignancy.
3. Causes
Alterations in FLi1 function are caused by genetic mutations, gene rearrangements, or abnormal overexpression. Mutations involving the FLi1 gene are strongly associated with Ewing sarcoma, where FLi1 plays a central role in tumorigenesis.
FLi1 also regulates the maintenance and differentiation of hematopoietic stem cells and is involved in angiogenesis. Dysregulation of these processes contributes to malignant transformation, disease progression, and altered cellular survival pathways.
4. Risk Factors
Risk factors related to Friend leukemia integration 1-associated disorders include genetic susceptibility to hematologic malignancies, sarcomas, and vascular tumors. Overexpression of FLi1 has been linked to poor prognosis in several cancers, including astrocytoma, non-small cell lung cancer, and endometrial carcinoma.
Friend leukemia integration 1 expression is also relevant in autoimmune diseases such as systemic lupus erythematosus, where it correlates with disease activity and inflammation. Germline variants in Friend leukemia integration 1 have been associated with platelet disorders, leading to bleeding tendencies and thrombocytopenia.
5. Prevention and Clinical Management
FLi1 is primarily used as a diagnostic and prognostic marker rather than a preventive screening tool. Detection is most commonly performed using immunohistochemistry (IHC) on formalin-fixed, paraffin-embedded tissue samples. Friend leukemia integration 1 shows nuclear staining, and endothelial cells serve as an internal positive control. Even low levels of positivity, such as staining in approximately 10% of cells, are sufficient to consider the marker positive.
Friend leukemia integration 1 is regarded as a gold-standard immunohistochemical marker for diagnosing angiosarcoma and other tumors of vascular origin, as well as for identifying vascular invasion in tumors. Positive staining is seen in Ewing sarcoma, endothelial neoplasms such as angiosarcoma and epithelioid hemangioendothelioma, Burkitt lymphoma, and lymphoblastic lymphomas. Negative staining is typical in most mature B-cell lymphomas and non-vascular soft tissue tumors, while borderline or variable expression may be observed in plasmablastic lymphoma and diffuse large B-cell lymphoma.
Clinically, Friend leukemia integration 1 has important diagnostic, prognostic, and therapeutic implications. In acute myeloid leukemia and acute promyelocytic leukemia, FLi1 expression is associated with poor prognosis and higher relapse risk. In breast cancer, FLi1 serves as a tumor biology marker, while in Ewing sarcoma, it is both a diagnostic marker and a potential therapeutic target.
Targeted therapy research highlights IL1RAP, a direct target of the EWS-Friend leukemia integration 1 fusion protein, as a promising surface antigen for immunotherapy due to its high expression in Ewing sarcoma and minimal expression in normal tissues.
